Jing Guo

Jing Guo

Auto-generated profile, based on publicly available information

Jing Guo

Department of Microbiology and Immunology, Stanford University School of Medicine, Palo Alto, CA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SSShan Sun
Shan Sun
LLLingjie LUO
Lingjie LUO
WLWenhua Liang
Wenhua Liang
QYQian Yin
Qian Yin
JGJing Guo
Jing Guo
FWFeng Wang
Feng Wang
Significance: Many millions of people take probiotics over the counter, but very little is known about what they do and whether they really work. Here we show that in mice, introducing Bifidobacterium , one of the most commonly used probiotics, not only colonizes the gut, but also alters the entire microbiotic landscape. We previously found that this treatment rescues mice from an otherwise fatal inflammatory syndrome brought on by anti–CTLA-4 antibody, a checkpoint inhibitor that often causes autoimmunity in humans undergoing cancer treatment. Here we show that this is effect is due, at least in part, to the effect of this probiotic treatment on regulatory CD4 + cells, whose metabolic and immune suppressive functions are altered. These CD4 + regulatory T cells are known to be a key mechanism in the control of autoreactivity in the immune system in both mice and humans. Thus, we found a direct connection between probiotic treatment and one of the known principal mechanisms for controlling excess immune responses.

15 April 2022 in Science
Verified
Journal Article
Open access
JLJing Li
Jing Li
MZMaxim Zaslavsky
Maxim Zaslavsky
YSYapeng Su
Yapeng Su
JGJing Guo
Jing Guo
MSMichael J. Sikora
Michael J. Sikora
MDMark M Davis
Mark M Davis
In this work, we find that CD8 + T cells expressing inhibitory killer cell immunoglobulin-like receptors (KIRs) are the human equivalent of Ly49 + CD8 + regulatory T cells in mice and are increased in the blood and inflamed tissues of patients with a variety of autoimmune diseases. Moreover, these CD8 + T cells efficiently eliminated pathogenic gliadin-specific CD4 + T cells from the leukocytes of celiac disease patients in vitro. We also find elevated levels of KIR + CD8 + T cells, but not CD4 + regulatory T cells, in COVID-19 patients, correlating with disease severity and vasculitis. Selective ablation of Ly49 + CD8 + T cells in virus-infected mice led to autoimmunity after infection. Our results indicate that in both species, these regulatory CD8 + T cells act specifically to suppress pathogenic T cells in autoimmune and infectious diseases.

30 January 2023 in Nature Materials
Verified
Journal Article
Open access
PDF file
QYQian Yin
Qian Yin
WLWei Luo
Wei Luo
VMVamsee Mallajosyula
Vamsee Mallajosyula
YBYang Bo
Yang Bo
JGJing Guo
Jing Guo
MDMark M Davis
Mark M Davis
The ideal vaccine against viruses such as influenza and SARS-CoV-2 must provide a robust, durable and broad immune protection against multiple viral variants. However, antibody responses to current vaccines often lack robust cross-reactivity. Here we describe a polymeric Toll-like receptor 7 agonist nanoparticle (TLR7-NP) adjuvant, which enhances lymph node targeting, and leads to persistent activation of immune cells and broad immune responses. When mixed with alum-adsorbed antigens, this TLR7-NP adjuvant elicits cross-reactive antibodies for both dominant and subdominant epitopes and antigen-specific CD8+ T-cell responses in mice. This TLR7-NP-adjuvanted influenza subunit vaccine successfully protects mice against viral challenge of a different strain. This strategy also enhances the antibody response to a SARS-CoV-2 subunit vaccine against multiple viral variants that have emerged. Moreover, this TLR7-NP augments antigen-specific responses in human tonsil organoids. Overall, we describe a nanoparticle adjuvant to improve immune responses to viral antigens, with promising implications for developing broadly protective vaccines.

31 March 2023 in Science Immunology
Verified
Journal Article
Closed access
RCRoshni Roy Chowdhury
Roshni Roy Chowdhury
JVJohn R. Valainis
John R. Valainis
MDMegha Dubey
Megha Dubey
LBLotta von Boehmer
Lotta von Boehmer
ESElsa Sola
Elsa Sola
YCYueh-Hsiu Chien
Yueh-Hsiu Chien
The response of gamma delta (γδ) T cells in the acute versus chronic phases of the same infection is unclear. How γδ T cells function in acute Mycobacterium tuberculosis (Mtb) infection is well characterized, but their response during persistent Mtb infection is not well understood, even though most infections with Mtb manifest as a chronic, clinically asymptomatic state. Here, we analyze peripheral blood γδ T cells from a South African adolescent cohort and show that a unique CD8 + γδ T cell subset with features of “memory inflation” expands in chronic Mtb infection. These cells are hyporesponsive to T cell receptor (TCR)–mediated signaling but, like NK cells, can mount robust CD16-mediated cytotoxic responses. These CD8 + γδ T cells comprise a highly focused TCR repertoire, with clonotypes that are Mycobacterium specific but not phosphoantigen reactive. Using multiparametric single-cell pseudo-time trajectory analysis, we identified the differentiation paths that these CD8 + γδ T cells follow to develop into effectors in this infection state. Last, we found that circulating CD8 + γδ T cells also expand in other chronic inflammatory conditions, including cardiovascular disease and cancer, suggesting that persistent antigenic exposure may drive similar γδ T cell effector programs and differentiation fates.

16 January 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JGJing Guo
Jing Guo
RCRoshni Roy Chowdhury
Roshni Roy Chowdhury
VMVamsee Mallajosyula
Vamsee Mallajosyula
JXJianming Xie
Jianming Xie
MDMegha Dubey
Megha Dubey
YCYueh-Hsiu Chien
Yueh-Hsiu Chien
γδ T cells are essential for immune defense and modulating physiological processes. While they have the potential to recognize large numbers of antigens through somatic gene rearrangement, the antigens which trigger most γδ T cell response remain unidentified, and the role of antigen recognition in γδ T cell function is contentious. Here, we show that some γδ T cell receptors (TCRs) exhibit polyspecificity, recognizing multiple ligands of diverse molecular nature. These ligands include haptens, metabolites, neurotransmitters, posttranslational modifications, as well as peptides and proteins of microbial and host origin. Polyspecific γδ T cells are enriched among activated cells in naive mice and the responding population in infection. They express diverse TCR sequences, have different functional potentials, and include the innate-like γδ T cells, such as the major IL-17 responders in various pathological/physiological conditions. We demonstrate that encountering their antigenic microbiome metabolite maintains their homeostasis and functional response, indicating that their ability to recognize multiple ligands is essential for their function. Human γδ T cells with similar polyspecificity also respond to various immune challenges. This study demonstrates that polyspecificity is a prevalent feature of γδ T cell antigen recognition, which enables rapid and robust T cell responses to a wide range of challenges, highlighting a unique function of γδ T cells.

21 May 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
QYQian Yin
Qian Yin
WYWong Yu
Wong Yu
CGCaitlin L. Grzeskowiak
Caitlin L. Grzeskowiak
JLJing Li
Jing Li
HHHuang Huang
Huang Huang
MDMark M Davis
Mark M Davis
Significance: Tumors are often infiltrated by T lymphocytes recognizing either self- or mutated antigens but are generally inactive. Self-specific CD8+T cells are particular characteristics of tumor types with lower tumor mutation burden and poorer outcomes. Unlike foreign-specific T cells, they have been curiously resistant to stimulation with cognate antigens. We developed an innate immunity-stimulating nanoparticle to activate tumor-infiltrating CD8+T cells recognizing both self- and neoantigens in a potent yet safe manner. This resulted in effective tumor growth inhibition or elimination in two murine tumor models and the activation of endogenous T cells in patient-derived tumor organoids across three cancer types. This strategy represents a promising pathway for broadly effective cancer immunotherapy.